Canopy Growth (Nasdaq: $CGC) Stock Hub: Q1 FY2027 Revenue Up 13% to C$81.2 Million, the Adjusted EBITDA Loss Narrowed 59%, and the September 25 Shareholder Vote

01 Latest Update — August 7, 2026

Three things changed for $CGC between the FY2026 annual report and the end of July 2026, and all three are dated. The DEA rescheduling hearing closed on July 15 without a decision, Canopy filed a preliminary proxy on July 17 asking shareholders to authorise a share consolidation of between one-for-five and one-for-fifteen, and on August 7 the company reported first-quarter fiscal 2027 results before the U.S. market opened.

Q1 FY2027 results, reported August 7, 2026

Net revenue of C$81.2 million for the quarter ended June 30, 2026, up 13% year over year, with growth in every business. The adjusted EBITDA loss narrowed 59% to C$3.2 million from C$7.9 million, and adjusted gross margin rose to 31% from 25%. Free cash flow moved the other way, to negative C$25.7 million from negative C$11.6 million.

What the quarter showed

Every reported line of the profit and loss account improved, and the cash line did not. Net revenue reached C$81.2 million, up 13% against the quarter ended June 30, 2025. Cannabis net revenue was C$65.1 million, up 14%, split between Canadian medical at C$25.8 million and up 22%, Canadian adult-use at C$29.7 million and up 10%, and international markets at C$9.6 million and up 10%. Storz & Bickel added C$16.1 million, up 6%.

The medical line carried the quarter, helped by a larger insured customer base and by the MTL Cannabis acquisition, and held that growth despite the Canadian government cutting the Veterans Affairs Canada reimbursement rate for medical cannabis. Adult-use growth came from flower volume acquired with MTL rather than from the existing base, offset by fewer opportunistic bulk sales.

Margins moved in the right direction. Consolidated gross margin was 27% against 25%, and adjusted gross margin 31% against 25%, the adjusted figure excluding C$2.6 million of inventory step-up charges that came with the MTL purchase. The cannabis segment is the exception: its reported gross margin fell to 22% from 24%, and only on the adjusted basis does it improve, to 26% from 24%.

Below the margin line the improvement is real. Net loss narrowed to C$14.6 million from C$44.9 million, and the adjusted EBITDA loss to C$3.2 million from C$7.9 million, the 59% reduction the company put in its headline. On that measure the FY2027 target of positive adjusted EBITDA is within a few million dollars a quarter.

The line that moved the other way. Free cash flow was negative C$25.7 million against negative C$11.6 million a year earlier, and cash used in operating activities negative C$25.0 million against negative C$10.3 million. Cash and equivalents fell to C$336.6 million at June 30 from C$364.7 million at March 31, a drop of C$28.1 million in three months. Accounting profitability and cash generation are moving in opposite directions, and it is the second that funds the company between here and the FY2027 target.

Share consolidation vote: September 25, 2026

The definitive proxy filed August 7 asks shareholders to approve a reverse split at a ratio chosen by the board within a one-for-five to one-for-fifteen range, exercisable at any time before September 25, 2027. Canopy mailed the meeting materials on August 17 and is pushing for early voting: the record date was July 31, proxies must be in by 1:00 p.m. ET on September 23, and Nasdaq rules require a quorum of one third of the outstanding shares, which the company says is not guaranteed given its shareholder base.

DEA process: no decision, no deadline

The administrative hearing on broader rescheduling ended July 15 after seventeen hearing days. Post-hearing briefs were filed on August 17: the Government asks the tribunal to recommend Schedule III, and every designated party asks that marijuana stay in Schedule I. Nothing in the statute binds the DEA Administrator to a decision date.

The share price context matters for how these three items interact. Canopy closed at US$0.8942 on July 28, 2026. Counting last-sale closing prices from commercial market data, the stock had closed below US$1.00 for seventeen consecutive sessions at that point, the last close at or above the dollar mark having been recorded on July 2. Nasdaq’s minimum bid price rule is measured on the closing bid over thirty consecutive business days, which is a slightly different series from the one used here, so the count should be read as an approximation rather than an official tally. On that approximation, and only if weakness persists uninterrupted, the threshold would fall in the second week of August. No deficiency notice has been received: a full-text search of Canopy’s SEC filings and investor-relations releases through July 29, 2026 returns no such disclosure, and the FY2026 Form 10-K does not mention the minimum bid price rule at all.

That sequence explains the timing of the proxy rather than the other way round. The company is asking for the authorisation before it needs it, exactly as it did at the 2025 annual meeting, when shareholders approved a substantially identical resolution that the board never used. The proxy language itself is explicit about the mechanism, noting that a deficiency letter follows thirty consecutive business days below the threshold.

Nothing else of an operating nature has been disclosed since the annual report. Between June 16 and August 7, 2026, the SEC record for Canopy contains a Form S-8 on June 17, insider Form 4 filings on June 22 and June 29, the preliminary proxy on July 17, and the Form 8-K of August 7 carrying the first-quarter FY2027 results. The two company releases in the window are the July 21 announcement that Luc Mongeau will present at the Canaccord Genuity Growth Conference on August 11 and the July 24 earnings-date notice. The operating question the annual report left open has now had its first answer. The FY2027 adjusted-EBITDA target survived contact with the first reported quarter on the profit and loss account, where the loss narrowed to C$3.2 million, but not on the cash flow statement, where the outflow widened to C$25.7 million.

02 Next Catalyst Watch

For the first time in months the $CGC calendar is dense rather than empty. Two company events and one regulatory milestone fall inside a five-week window, and the annual meeting that follows in September carries a vote with direct mechanical consequences for the share count.

Company catalyst

The August 7 results were the first quarter in which MTL integration, post-acquisition inventory normalisation and the medical growth trend could be read together rather than inferred. They showed margin repair and a widening cash outflow in the same three months.

Structural catalyst

The September 25 consolidation vote does not by itself change value, but the ratio the board eventually selects, and whether it acts at all, is a direct signal about how management reads the share price.

Policy catalyst

The DEA record is closed but the outcome is open-ended. A recommended decision could land at any time after August 17, and the sector has repeatedly repriced on procedural news alone.

03 Executive Summary

Canopy Growth remains one of the most recognizable cannabis tickers in North America, but the reason to follow $CGC in 2026 is very different from the reason traders followed it during the original cannabis mania. The old story was market access, legalization optimism and brand land-grab. The current story is narrower, cleaner and more demanding: can a smaller, recapitalized Canopy convert medical cannabis scale, MTL Cannabis assets, selected adult-use innovation and international medical demand into a credible path toward operating break-even?

Fiscal 2026 gave the market a mixed but materially updated picture. Consolidated net revenue reached C$284.6 million for the year, up 6% versus FY2025, while Q4 FY2026 net revenue was C$71.2 million, up 10% year over year. Cannabis net revenue was stronger than the consolidated headline, rising 15% for FY2026 and 20% in Q4 on figures that are rounded to the nearest hundred thousand, helped by Canadian medical growth, adult-use product innovation and a Q4 rebound in international markets after earlier European supply constraints. At the same time, Storz & Bickel, historically one of Canopy’s higher-quality assets, declined 14% for the full year and 14% in Q4. The company attributed the revenue decline to consumer softness and the comparison against stronger prior-year periods, and cited higher U.S. import tariffs as a pressure at the gross-margin level.

The balance sheet is no longer the same existential problem it was during the worst phase of the cannabis unwind. Canopy ended FY2026 with C$364.7 million in cash and cash equivalents, C$16.2 million of current long-term debt and C$217.1 million of long-term debt, giving total debt of C$233.4 million and a stated net cash position of C$131.3 million after a strategic recapitalization. Free cash outflow improved from C$176.6 million in FY2025 to C$69.1 million in FY2026. Adjusted EBITDA remained negative at a C$20.2 million loss for the year, but the company is guiding toward positive adjusted EBITDA during FY2027, with management expecting improvements to be more visible in the second half of the fiscal year as MTL integration progresses.

That is the bull case in one sentence: Canopy has finally bought itself time, refocused the operating base, added MTL Cannabis, and now has a measurable FY2027 profitability target. The bear case is equally simple: the company is still lossmaking, shares outstanding have increased sharply, Storz & Bickel is not currently growing, prior-period financial statements required restatement for warrant accounting, and the U.S. optionality remains structurally complicated because Canopy USA is unconsolidated and dependent on legal, exchange and regulatory permissibility.

What improved

Net cash position, lower free cash outflow, better cannabis revenue growth, Canadian medical scale, MTL acquisition and FY2027 adjusted EBITDA target.

What still needs proof

Gross margin durability, MTL integration, actual EBITDA break-even, Europe execution, adult-use competitiveness and Storz & Bickel stabilization.

Why traders watch it

$CGC remains a liquid cannabis beta vehicle tied to Schedule III headlines, Canadian LP sentiment and retail-sector momentum.

Main red flags

Losses, dilution, restatement history, sub-$1 price sensitivity, cannabis policy risk and the gap between U.S. optionality and actual consolidated economics.

04 Quick Snapshot

Financial figures are in Canadian dollars as reported by the company; share price and market capitalisation are in U.S. dollars. Prices as of the close of July 28, 2026.

05 Market Snapshot and Sector Context

Canopy is a policy-beta stock trading inside a sector that has spent 2026 giving back most of what it gained in the two rallies that framed the year: the December 2025 executive order that pushed rescheduling onto the agenda, and the April 2026 order that delivered a narrower version of it than the market had priced.

The pattern in that table is the whole argument in miniature. The instruments closest to a U.S. tax outcome have fallen least; the Canadian producers, which do not touch the U.S. THC market and therefore cannot capture 280E relief, have fallen most. Canopy sits between the two groups only because of Canopy USA, and Canopy USA is an unconsolidated option rather than a revenue line.

On the company’s own numbers, the Form 10-K discloses that between April 1, 2025 and June 11, 2026 the closing price on Nasdaq ranged from a low of US$0.83 to a high of US$1.93. The stock currently sits in the lower quarter of that range. Market data providers put short interest at roughly 5.6% of the float with a short ratio near four, which is high in absolute terms but modest for this sector: the comparable readings for Tilray and Aurora are above 12%. Average daily volume has thinned materially, from more than 20 million shares a day around the December 2025 spike to between one and three million through most of July.

The Canadian domestic market that generates most of Canopy’s revenue is not helping. Statistics Canada retail data show sales still growing in absolute terms, with a record C$503.7 million in December 2025, while retail prices fell 3.2% year over year in March 2026 and wholesale volumes declined 29% year over year in January. Inventories have not fallen with them. Excise duty is structured as the greater of C$1.00 per gram or 10% of the producer price. Published industry analysis of licensed-producer filings puts its weight at 24.3% of gross revenue in 2024, against 11.2% in 2019. That is the structural reason Canadian producers keep growing revenue without generating cash.

Germany, the other half of the growth argument, is genuinely large and genuinely decelerating. Federal institute import data show 32.5 tonnes in 2023, 71.1 in 2024 and 201.1 in 2025, then 50.5 tonnes in the first quarter of 2026: still up around 35% year over year, but the first quarterly decline in two years, with average per-gram prices down about a third between early 2025 and mid-2026. Canada supplied a little over half of German imports in that quarter. A restrictive amendment banning telemedicine prescribing and mail order cleared the German cabinet in October 2025 and had its first Bundestag reading in December, but remains stuck in committee, so both channels were still legal as of late July 2026.

Prices and performance are calculated from closing prices on December 31, 2025 and July 28, 2026. Short interest and volume figures come from commercial market-data providers and are indicative rather than filed data.

06 What Canopy Growth Is Today

Canopy Growth is a cannabis company, but the label is too broad to describe the current investment story. It is better understood as a three-part platform: Canadian cannabis, international medical cannabis and devices, with a separate U.S. THC option sitting through Canopy USA. The company sells medical and adult-use cannabis products in Canada, serves medical patients through channels such as Canada House Clinics and Abba Medix, owns or licenses brands including Tweed, 7ACRES, DOJA, Deep Space, DeeLish, Claybourne, MTL Cannabis, Low Key by MTL and R’belle, and owns Storz & Bickel, the German vaporizer business.

This matters because the old “Canadian LP” framework is incomplete. A simple cannabis cultivation story would mostly depend on wholesale prices, provincial distribution, excise taxes and retail share. Canopy still faces all of those issues, but management is now trying to build a more balanced platform around medical cannabis patients, higher-quality flower supply, consumer product innovation, European medical growth, and a U.S. option that could become more valuable if federal cannabis policy continues to shift.

The MTL Cannabis acquisition changed the shape of the company. Canopy completed the transaction in March 2026, acquiring all issued and outstanding MTL shares. Management framed the deal as a way to create Canada’s leading medical cannabis platform by revenue, strengthen premium flower supply, add disciplined operating assets and support the company’s FY2027 adjusted EBITDA objective. The transaction also brought MTL leadership into Canopy’s operating structure: Michael Perron, previously chief executive of MTL Cannabis, is listed on the company’s leadership page as Chief Operating Officer, with responsibility for cultivation, manufacturing, supply chain and distribution.

For investors and traders, that makes CGC a turnaround proof story. It is no longer enough for the company to say cannabis is a large future market. The market has heard that before. The burden now is execution: stronger revenue quality, real gross-margin stability, lower cash burn, less reliance on equity issuance, and a clearer path from brand relevance to operating cash generation.

07 Why $CGC Matters Now

The reason to look at $CGC at the end of July 2026 is that the two questions that dominated the first half of the year have both been answered, and both answers were narrower than the market originally priced.

The first question was operational: what does Canopy actually look like after the reset? That was settled on June 15, when the company reported FY2026, filed a comprehensive annual report incorporating restated prior periods, and confirmed a net cash position for the first time in years. The answer is a smaller company with C$284.6 million of revenue, a repaired balance sheet, a material weakness in internal control that has not yet been remediated, and a target of positive adjusted EBITDA at some point during FY2027.

The second question was regulatory: does the U.S. rescheduling process go beyond the medical-only order issued in April? That is now in the hands of an administrative law judge, with the evidentiary record closed since July 15 and no deadline attached to what comes next. The market spent the first half of 2026 trading a binary that has quietly become an open-ended administrative timetable.

What replaces those two questions is more specific and, for once, calendared. August 7 produced the first quarter that includes MTL Cannabis for a full three months. September 25 produces a shareholder vote on a share consolidation. In between sits the Nasdaq bid-price mechanism, whose thirty-session window on the current run of sub-dollar closes began in early July, and whose mechanics the company has now spelled out in a public filing. The first two items have fixed dates; the third depends on where the price closes.

The price level is part of the setup rather than incidental to it. A stock at eighty-nine cents behaves differently from the same business at three dollars: it attracts momentum flow on policy headlines, it makes equity issuance more expensive in percentage terms, and it puts exchange mechanics into the conversation. Canopy has been here before. The company completed a one-for-ten consolidation effective December 15, 2023 for exactly this reason, and the proxy filed this month asks for authority to do a version of it again.

From a sector perspective, Canopy remains less economically exposed to U.S. tax reform than the multi-state operators, but far easier for U.S. retail investors to trade. That is the recurring tension in this sector: the cleanest beneficiaries of reform are often the least accessible instruments, while the fastest price reaction shows up in liquid Nasdaq tickers such as $CGC and $TLRY.

08 The FY2026 Numbers: What Improved and What Did Not

Fiscal 2026 should not be described as a clean breakout year. It was a repair year with visible progress and visible remaining weaknesses. The headline revenue growth is positive, the cannabis segment is improving, cash burn is much lower, and net cash is better. But the company still reported a large net loss, still posted negative adjusted EBITDA, still absorbed impairment and restructuring costs, and still needs to prove that adjusted margins can hold after MTL integration and inventory cleanup.

The good news

The good news is that the company is not simply shrinking. Cannabis net revenue grew, Canadian medical cannabis continued to expand, adult-use cannabis improved for the full year, and free cash outflow was reduced by more than C$100 million versus FY2025. Canopy also ended FY2026 with a much stronger cash balance, helped by financing and recapitalization actions.

The uncomfortable part

The uncomfortable part is that the path remains fragile. Gross margin as reported fell to 12% in Q4 FY2026 from 16% in the prior-year quarter, and full-year gross margin fell to 24% from 30%. The company incurred C$10.7 million of inventory charges in Q4 FY2026, primarily tied to a review of cannabis inventory levels after the MTL Cannabis acquisition. Adjusted gross margin looked better, especially in Q4, but the market will want to see reported margin quality, not only adjusted improvement.

The clean read: FY2026 reduces the survival-risk narrative, but it does not yet prove durable profitability. The market can now give Canopy more credit for liquidity and strategic focus, but the next re-rating requires evidence that the FY2027 adjusted EBITDA target is realistic.

09 MTL Cannabis: Why the Acquisition Matters

MTL Cannabis is central to the new Canopy story because it gives the company more than just another brand. It gives Canopy a stronger medical platform, additional premium flower capacity, a larger Canadian patient network, cultivation depth, and a more coherent bridge between Canadian supply and international medical demand.

The transaction closed on March 16, 2026. Canopy acquired 100% of MTL’s issued and outstanding shares, issued approximately 41.2 million Canopy common shares and made a cash payment of approximately C$18.5 million as consideration to MTL shareholders. Additional shares were issued to certain former Montreal Cannabis Medical shareholders in exchange for a release of prior obligations, with those shares subject to an 18-month transfer restriction.

Strategically, management highlighted expected annualised run-rate cost synergies of approximately C$10 million within 18 months. The deal also added MTL’s cultivation and post-harvest assets, Canada House Clinics, Abba Medix, medical cannabis distribution infrastructure, and brands including MTL Cannabis, Low Key by MTL and R’belle. The company described the combined platform as Canada’s leading medical cannabis business by revenue.

The market will not simply accept that as value creation by default. The acquisition introduces integration risk, inventory review charges, potential share resale overhang and the normal danger that synergies arrive slower than promised. But from an operating perspective, it gives Canopy a more credible answer to a key question: where does higher-quality cannabis supply come from, and how does the company support medical demand in Canada and Europe without relying only on legacy brands?

Strategic benefit

Strengthens medical cannabis scale, flower supply and international medical-market readiness.

Operational benefit

Adds cultivation expertise, patient channels, clinics and medical distribution assets.

Financial target

Annualised run-rate cost synergies of about C$10M within 18 months, according to the company.

Risk

Integration, dilution, inventory charges and execution complexity remain central watch items.

10 Canada Medical Cannabis: The Core Quality Pillar

If there is one operating area that should receive the most serious attention, it is Canadian medical cannabis. In Q4 FY2026, Canada medical cannabis net revenue increased 27% year over year to C$25.3 million. For FY2026, the segment increased 18% to C$90.8 million. That growth was driven by factors including insured patient growth and a broader assortment of cannabis products offered to customers.

Medical cannabis is important because it is less dependent on the same retail hype cycle that made adult-use cannabis so volatile. It is still regulated, competitive and exposed to reimbursement changes, but it can support a more durable business model if the company can defend patient relationships, maintain quality, improve fulfillment and leverage MTL’s medical infrastructure.

Reimbursement is part of that equation. Canopy has specifically discussed pricing actions, product mix refinements and patient retention efforts intended to minimize the impact of reduced medical cannabis reimbursement from Veterans Affairs Canada. That means medical cannabis is not automatically a margin paradise. It is a stronger strategic pillar than commodity adult-use flower, but it still requires disciplined execution.

The real question for FY2027 is whether Canopy can convert Canadian medical leadership into a platform advantage. If medical cannabis grows while adult-use stabilizes and Europe expands, the company can begin to look less like a broken legacy cannabis producer and more like a focused medical-and-consumer platform. If medical growth slows, the FY2027 adjusted EBITDA target becomes harder to believe.

11 Adult-Use Cannabis: Innovation Helps, But Competition Remains Brutal

Canopy’s Canadian adult-use cannabis business grew 20% for FY2026, reaching C$94.5 million in net revenue. The company pointed to infused pre-roll joints, All-In-One vaporizers and product innovation across categories such as vapes, high-THC flower, pre-rolls and edibles. The launch of DeeLish, with high-THC flower and pre-roll formats, and the continued expansion of Claybourne products show that Canopy is trying to meet the current consumer market where demand actually is rather than where the industry hoped it would be years ago.

The Q4 number was less exciting: Canada adult-use cannabis net revenue increased only 1% year over year to C$20.6 million. That does not erase the full-year growth, but it does show why adult-use remains a difficult base for a turnaround thesis. Consumer cannabis can be promotional, provincial distribution can be uneven, price pressure can be intense, and product cycles can fade quickly.

Claybourne’s Frosted Flyers, which the company said won Best Infused Pre-Roll at the 2026 Grow Up Awards, gives Canopy a brand proof point, and the company expanded the Frosted Flyers lineup with new variety pack formats in June 2026. But awards and product expansions are not enough on their own. The market will measure whether brand momentum translates into repeat revenue, shelf strength, better mix and gross-margin improvement.

The adult-use business therefore belongs in the “watch for proof” category. It can help the turnaround, especially if infused pre-rolls and vapes remain strong categories, but it is not the same quality of revenue as a durable medical platform. The best-case scenario is not just higher adult-use sales; it is higher adult-use sales with better mix and fewer inventory write-downs.

12 Europe and International Medical Cannabis

Europe is one of the areas where Canopy wants investors to look beyond Canada. In Q4 FY2026, international markets cannabis net revenue increased 68% year over year to C$8.6 million as the company addressed supply-chain challenges in Europe. For the full fiscal year, however, international cannabis revenue declined 7% to C$28.7 million. That contrast is important: the Q4 rebound is encouraging, but FY2026 as a whole still showed the cost of earlier execution constraints.

The May 2026 relaunch of Tweed in Germany with new MTL-derived strains is a concrete example of the post-MTL strategy. Canopy launched Pablo’s Revenge, Dante’z Inferno and Frost’d Flakes under the Tweed brand in Germany and said up to five additional MTL-derived strains were expected to follow in June 2026, with further portfolio expansion planned through the year. Management framed Germany as one of the fastest-growing medical cannabis markets globally and described the European Union as a major long-term opportunity.

The long-term angle is real, and it is also slower than the headlines suggest. Europe is not a magic switch. Medical cannabis markets differ country by country, reimbursement rules matter, physician adoption matters, and supply consistency matters. Canopy’s advantage is that MTL can support higher-quality flower supply while legacy brands such as Tweed may still have recognition. The risk is that competitors are also pushing into Germany and broader Europe, and regulatory complexity can slow the pace of growth.

For the stock, Europe matters because it can help reposition Canopy away from the damaged Canadian recreational-only narrative. If Germany and other international medical markets grow while Canada medical holds and MTL integration improves supply, the company may earn a more credible medical-cannabis multiple. If Europe disappoints again, the story becomes more dependent on U.S. headlines and retail volatility.

13 Storz & Bickel: Still Valuable, But No Longer an Easy Growth Anchor

Storz & Bickel remains one of Canopy’s most recognizable non-cannabis-plant-touching assets. It gives the company exposure to vaporization devices, a global premium-device brand and a business that historically carried a stronger margin profile than commodity cannabis. In theory, this should be a quality asset inside the Canopy portfolio.

Fiscal 2026 was not a clean growth year. Storz & Bickel net revenue was C$16.8 million in Q4 FY2026, down 14% year over year, and C$70.7 million for the full year, also down 14%. The company attributed the decline to comparison against strong prior-year sales, continued consumer economic uncertainty and, at the gross-margin level, increased tariffs on imports into the United States and shifts in geographic mix. The new VEAZY vaporizer, launched in September 2025, helped offset pressure but did not fully reverse the segment decline.

The key question is whether Storz & Bickel stabilizes in FY2027. If it does, it can remain an important contributor to gross profit and brand quality. If it keeps shrinking, Canopy loses one of the assets that used to make the story look more differentiated than a pure Canadian cannabis producer.

Storz & Bickel is not broken, but it is under pressure. It remains a valuable asset that has yet to confirm renewed revenue and margin, which is a different thing from a guaranteed premium growth engine.

14 Canopy USA and the U.S. THC Option

Canopy USA is the part of the story that gives $CGC its U.S. cannabis optionality, and it is also the part most frequently misread. Canopy Growth holds an unconsolidated, non-controlling interest in Canopy USA, LLC. Canopy USA and its subsidiaries in turn hold 100% of Wana, approximately 77% of Jetty, 100% of Acreage Holdings and 64,564,487 common shares of TerrAscend.

The structure exists for a reason. Nasdaq’s position is that a listed company consolidating assets and revenue generated from activities that violate U.S. federal law cannot remain listed. Canopy states the consequence directly in its own annual report: if the results of Canopy USA were consolidated, the Canopy shares would likely be delisted from Nasdaq. The non-consolidation is therefore not an accounting preference, it is the condition of the listing.

A development in June 2026 tightened the structure further and received almost no attention. On June 15, 2026, in the first amendment to the January 2026 loan agreement, the lenders imposed what the filing calls an Exchange Restriction: Canopy and certain subsidiaries are prohibited from converting their non-voting shares into Canopy USA Class B shares before the date on which stock-exchange rules permit it. In plain terms, the creditors have placed a contractual lock on the mechanism through which Canopy would convert its economic interest into control. Anyone modelling a scenario where a favourable rescheduling outcome is followed by rapid consolidation of Canopy USA has to route that scenario through the lenders first.

In practical terms, Canopy has a structured economic bridge to U.S. THC assets, and the bridge is currently locked at both ends, once by exchange rules and once by the loan agreement. A broader Schedule III outcome could improve the value of what sits on the other side. It would not, by itself, open the bridge.

Canopy USA is neither negligible nor a hidden operating business. It is an option with real underlying assets and real contractual constraints. Options acquire value when the regime changes; they can also stay discounted for years when the timing, the legality and the exchange rules all remain unresolved at once.

15 Schedule III: What It Means for $CGC

The single most common error in cannabis coverage this year has been treating the April 2026 order as general rescheduling. It was not. Understanding exactly what was moved, and what was left behind, is the difference between reading the sector correctly and trading a headline.

What the April order actually did

On April 23, 2026 the Department of Justice announced, and on April 28 the Federal Register published, a final order signed by the Acting Attorney General moving certain marijuana products into Schedule III. The order relies on section 811(d)(1) of the Controlled Substances Act, the treaty-obligation route tied to the 1961 Single Convention on Narcotic Drugs. That route matters procedurally: it bypasses the scientific findings and the notice-and-comment process required under sections 811(a) and (b), which is precisely the basis on which the order is now being challenged.

The scope is narrow. Marijuana, its extracts and plant-derived delta-9 THC move to Schedule III only where they are contained in an FDA-approved pharmaceutical product, or where they are subject to a state licence for the manufacture, distribution or dispensing of marijuana for medical purposes. Everything else stays in Schedule I: unlicensed cultivation, bulk marijuana, and any material not yet incorporated into an approved product. Adult-use cannabis is not covered. Synthetic THC is not covered. The order also introduced permit requirements for import and export and an expedited DEA registration path for holders of state medical licences.

Where the broader process stands

The broader proposal, the one that would move marijuana as a class, remains the proposed rule from May 2024, revived by the hearing notice published on April 28, 2026. The administrative hearing opened on June 29, 2026 before Chief Administrative Law Judge Derek C. Julius, ran for seventeen hearing days, and closed with final arguments on July 15, 2026. The judge ordered post-hearing briefs, optional and capped at fifty pages, by August 17, 2026.

What follows is the part that matters for anyone modelling a timeline. Judge Julius will issue a recommended decision that is not binding and for which no date has been set. Parties then have twenty days from receipt to file exceptions. The complete administrative record then passes to the DEA Administrator, Terry Cole, who decides. No provision of law imposes a deadline on that decision. Any final rule would then be published in the Federal Register and would itself be appealable. Anyone quoting a specific date for a broad Schedule III outcome is quoting a guess.

The composition of the hearing itself is part of the picture. The designated participants included state attorneys general from Nebraska, Idaho and Indiana, Smart Approaches to Marijuana, a drug-screening trade association, a state bureau of investigation, an impaired-driving victims group and two individual clinicians. Louisiana was designated in April and withdrew in June by order of the judge. No cannabis operator supporting rescheduling was among them. The evidentiary record was therefore built largely by parties opposed to the change.

The briefs arrived on the deadline and run to 274 pages. The Government brief asks for a recommendation to move marijuana to Schedule III, leaning on an Office of Legal Counsel opinion that found the traditional five-part test for accepted medical use insufficient because it ignores state-sanctioned programmes, and on the HHS finding of more than 30,000 practitioners treating over six million patients in 43 jurisdictions. The opposing briefs argue the proponent has not met its burden of proof, that the two-part test was built for this proceeding, and, in one filing, that the Attorney General had no authority to issue the notice of proposed rulemaking at all. The briefs are not posted on the DEA docket, which as of August 19 still lists only orders.

The litigation running alongside it

Three petitions challenging the April order have been consolidated before the D.C. Circuit: one filed May 4, 2026 by Smart Approaches to Marijuana and a screening association; one filed May 22 by Nebraska, Indiana and Louisiana, with Louisiana withdrawing on May 29; and one filed May 28 by a coalition including physicians, a treatment provider and a pharmaceutical developer arguing competitive disadvantage. A motion to stay the order was filed on June 9 and the government responded on July 2, contesting the petitioners’ standing. As of July 29, 2026 the court had not ruled on the stay and no oral argument date on the merits was on the public docket. The April order remains in force in the meantime.

Tax, banking and the limits of the story

Because section 280E denies deductions and credits only for trafficking in Schedule I or II substances, the reclassification removes that barrier for activities that, as a result of the order, no longer involve a Schedule I or II substance. Treasury and the IRS said on April 23, 2026 that guidance would follow on how businesses with mixed medical and adult-use operations should allocate expenses, and on a transition rule under which relief would apply to the entire fiscal year containing the effective date rather than being split mid-year. As of July 29, 2026 no formal IRS notice or revenue procedure had been published: the guidance has been announced, not issued.

On banking, the SAFE and SAFER Banking Act was reintroduced in both chambers on June 24 and 25, 2026, with a bipartisan Senate group behind it. It has been referred to committee and has not been voted on. It does not address 280E.

Two federal agencies made the practical limits explicit within weeks of the April order. The Department of Transportation confirmed on May 15, 2026 that a state medical card is not a legitimate medical explanation for a positive test under its rules, and the Army reconfirmed its own prohibition on May 14. Schedule III is a controlled-substance classification, not permission.

16 Restatement and Internal Control: Where It Stands Now

Canopy disclosed on May 15, 2026 that previously issued financial statements for fiscal 2024, fiscal 2025 and certain interim periods should no longer be relied upon, because certain share-settled warrants with U.S.-dollar exercise prices had been classified as equity when, given the company’s Canadian-dollar functional currency, they should have been classified as liabilities and remeasured at fair value each reporting date. The company also voluntarily sought a management cease trade order covering certain directors and officers while the refiling was completed.

The refiling was completed on June 15, 2026 through a comprehensive Form 10-K incorporating the restated periods, with the March 31, 2025 balance sheet labelled as restated. The economic content of the error is genuinely technical and non-cash: it does not change revenue, gross margin, operating cash flow, adjusted EBITDA or the cash balance. The warrant derivative liability that now sits on the balance sheet, C$27.5 million at March 31, 2026, is a direct product of the reclassification.

What has not been resolved is the control question, and this is the part that deserves attention twelve months from now rather than twelve days. In the FY2026 annual report the CEO and CFO concluded that both disclosure controls and internal control over financial reporting were not effective as of March 31, 2026, because of a material weakness in the review and approval of the accounting implications of equity-linked instruments. The auditor, PKF O’Connor Davies, issued its own report on the effectiveness of internal control. MTL Cannabis was excluded from the assessment under the SEC accommodation that applies in the first year after an acquisition. The remediation plan involves engaging third-party technical experts for new equity instrument issuances, additional training and increased oversight. The material weakness was not remediated as of the filing date.

The restatement itself is closed. The control environment that produced it is still being rebuilt, and the company issued warrants again in January 2026 as part of the recapitalisation. For a turnaround equity that has asked the market for capital repeatedly, clean reporting is part of the credibility being rebuilt, and it is the cheapest part to get right.

The auditor then changed. On August 7, 2026 PKF O'Connor Davies resigned with immediate effect, and the stated reason is not about Canopy: the firm is stepping back from the cannabis sector. The Form 8-K records no disagreements over accounting principles or disclosure, and the reportable events it lists are the ones already known, namely the adverse opinion on internal control at March 31, 2026 and the restatement. The audit committee engaged MNP LLP the same day for the fiscal year ending March 31, 2027, and shareholders are being asked to confirm that appointment at the September meeting. A new auditor arriving while a material weakness is still open means the first FY2027 audit is run by a firm with no prior exposure to the accounts.

Whether the management cease trade order was formally revoked after the June 15 refiling could not be confirmed from company filings or releases as of July 29, 2026. No disclosure announcing the revocation was located.

17 Capital Structure, Dilution and Runway

Canopy’s improved net cash position is real, and so is the price that was paid for it. At March 31, 2026 the company reported C$364.7 million in cash and equivalents, C$16.2 million of current long-term debt, C$217.1 million of long-term debt and total liabilities of C$421.1 million, producing a net cash position of C$131.3 million against net debt of C$172.6 million a year earlier. That is a swing of C$303.9 million in twelve months. It was funded almost entirely by issuing shares.

Common shares outstanding went from 183,865,295 at March 31, 2025 to 422,068,225 at March 31, 2026, and 422,154,892 by June 11, 2026, alongside 26,261,474 exchangeable shares. That is an increase of roughly 130% in a single fiscal year. Of that, C$374 million was raised through at-the-market equity programmes: 127,505,498 shares for C$238.4 million under the February 2025 programme, which was fully used by year-end, and 56,206,101 shares for C$135.8 million under the August 2025 programme. A further 41.2 million shares were issued as consideration for MTL Cannabis.

What is left available

The August 2025 at-the-market programme had US$102.0 million of capacity remaining as of June 11, 2026, and runs until June 5, 2027, subject to a filed sub-limit allowing up to US$50 million, or the Canadian equivalent, to be issued under certain of the qualifying documents. That capacity is the supply that can reach the market during a policy-driven rally without any further shareholder authorisation. An at-the-market facility does not mean shares are being sold today, but at a sub-dollar price it means every rally has a known potential seller.

The January 2026 debt package

The recapitalisation that repaired the balance sheet was completed on January 8, 2026 and its terms are more demanding than the headline net cash figure suggests. The company entered a senior secured term loan with a group of lenders led by JGB, drawing US$150 million in cash against a principal amount of US$162.1 million after an original issue discount of US$12.1 million. It bears interest at term SOFR with a 3.25% floor plus 6.25%, paid monthly in cash, and matures at the earlier of January 31, 2031 and 120 days before the convertible debentures mature. It is secured on substantially all assets. There is an exit fee of approximately US$6.5 million and, on repayments in the first year, a make-whole equal to twelve months of interest.

Two features carry the most weight. First, a financial covenant requires minimum unrestricted cash equal to the lesser of US$90 million and the outstanding principal. With C$336.6 million of cash on hand after the first quarter that is comfortable today, but it converts a large part of the cash balance into a covenant floor rather than free liquidity. Second, after the first anniversary of the first interest payment date each lender may require repayment of its pro rata share of up to US$3.0 million of principal per calendar month, in aggregate. From that point in 2027 onward, in other words, the lenders rather than the company can set part of the cash outflow schedule.

Alongside the loan, Canopy issued C$55.0 million of senior unsecured convertible debentures maturing July 8, 2031, carrying a 7.50% cash coupon paid semi-annually and convertible at C$1.83 per share, with a forced-conversion provision if the average closing trading price on the TSX exceeds C$2.75 over ten consecutive trading days. The lenders also received 18,705,578 warrants struck at US$1.30, and 12,731,481 warrants struck at C$2.16 were issued to the May 2024 investor under the exchange transaction that created the new debentures. The TSX line closed at C$1.26 on July 28, 2026, so the conversion price sits roughly 45% above the market and the forced-conversion trigger roughly 118% above it. Every one of those instruments is out of the money.

18 The Share Consolidation Vote and the Nasdaq Dollar Rule

This is the newest element of the $CGC setup and the one most likely to be misreported, because a reverse split is simultaneously the most visible corporate action a company can take and one of the least economically meaningful. It changes the denominator, not the business.

What is actually being proposed

In the preliminary proxy filed on July 17, 2026, Canopy asks shareholders to pass a special resolution consolidating all issued shares and exchangeable shares on the basis of a ratio to be determined by the board, in its sole discretion, within a range of one post-consolidation share for every five to fifteen pre-consolidation shares. The ratio must be a whole number and applies equally to both share classes. The authorisation may be exercised at any time before September 25, 2027, after which it lapses. The board may also abandon the resolution without a further vote, and the company states it will not proceed if doing so would prejudice its TSX or Nasdaq listings. Fractional shares would be surrendered for cancellation without payment.

The meeting is set for September 25, 2026 at 1:00 p.m. Toronto time, in virtual-only format, with a record date of July 31, 2026. Six other resolutions are on the ballot: the election of five directors, the appointment of MNP LLP as auditor for fiscal 2027 in place of PKF O’Connor Davies, an advance notice by-law, renewal of the omnibus incentive plan, say-on-pay and say-on-frequency. The definitive proxy was filed on August 7 and the meeting materials were mailed on August 17, with proxies due by 1:00 p.m. ET on September 23 and a quorum requirement of one third of the outstanding shares.

Why now

The proxy is unusually direct about the reason. It states that Nasdaq rules require a minimum bid price of at least US$1.00 per share, and that a deficiency letter follows if the closing price remains below that level for thirty consecutive business days. On last-sale closing prices, Canopy closed below one dollar for seventeen consecutive sessions through July 28, 2026, the last close at or above the mark having been recorded on July 2. The rule is measured on the closing bid rather than the last sale, so this count is an approximation. If the pattern continued uninterrupted, the thirty-session threshold would fall in the second week of August. A single qualifying close at or above US$1.00 resets the count.

As of July 29, 2026, no deficiency notice has been disclosed. A full-text search of Canopy’s SEC filings returns no minimum-bid-price notice since 2023, and the FY2026 Form 10-K does not mention the rule. Receiving such a notice, if it happened, would not be an immediate delisting: the standard remedy is a 180-day compliance period, extendable in some circumstances, during which the company can regain compliance by closing at or above a dollar for ten consecutive business days.

The proxy also notes that shareholders approved a substantially identical authorisation at the 2025 annual meeting and that the board never used it. The request is therefore a renewal of standing authority, not a decision to split.

How to read it

A reverse split does not create or destroy value on the day it happens. What it does is change the population of investors who can hold the stock, since many institutional mandates exclude sub-dollar securities, and change the optics of the share count, since 422 million shares at a fifteen-to-one ratio becomes 28 million. It also removes a mechanical listing risk without changing a single line of the income statement.

The empirical record for the sector is not encouraging, and Canopy’s own history illustrates it. The company completed a one-for-ten consolidation effective December 15, 2023, trading on a post-consolidation basis from December 20, for the same reason. Two and a half years later the share price is back below one dollar, after a period in which the share count grew from 183.9 million to 422.2 million. That sequence is the argument the market will make, and it is a fair one: a consolidation addresses the symptom while the cause is the rate of issuance.

The variable that matters more than the vote is what happens between now and the moment the board decides whether to use the authority. Q1 FY2027 showed credible progress toward the adjusted-EBITDA target on the reported loss, though not on cash. If the price also recovers above a dollar, the authorisation lapses unused a second time. If it does not, the ratio the board selects within that five-to-fifteen range becomes a public statement about how far management thinks the price needs to travel.

19 Management and Execution

Luc Mongeau’s role as CEO matters because Canopy is trying to reposition itself from cannabis land-grab to disciplined consumer and medical execution. His background is closer to consumer packaged goods, operations and brand management than to the early cannabis entrepreneur narrative. That is the profile Canopy needs if the company wants to be judged on portfolio focus, product mix, supply-chain discipline and cost control rather than on legalization slogans.

The FY2026 commentary from management is clear: Canopy believes it has reset the business, strengthened the balance sheet, acquired MTL Cannabis to drive the next phase of growth, and created a model capable of reaching positive adjusted EBITDA during FY2027. CFO Tom Stewart framed the stronger balance sheet as a way to reduce risk and expand strategic flexibility.

The market will judge management on measurable items. These include gross margin after MTL integration, cannabis segment profitability, Storz & Bickel stabilization, SG&A discipline, international medical supply execution, free cash flow progress and whether the FY2027 adjusted EBITDA target is met without simply leaning on aggressive adjustments.

The leadership additions from MTL also matter. Michael Perron, MTL’s former chief executive, is now Chief Operating Officer, and the company said at closing that MTL’s founders would support integration and cultivation in advisory roles. That should help operational execution, but integration still has to be proven in the numbers.

20 Analyst and Market Expectations

Analyst coverage of Canopy in 2026 is thin, stale in places, and unusually dispersed even by cannabis standards. It should be read as a map of disagreement rather than as a forecast.

The two individually documented 2026 actions point in opposite directions. Alliance Global’s Aaron Grey cut his target to C$1.80 from C$2.50 on February 7, 2026 while keeping a neutral rating. Roth Capital’s Bill Kirk carried a buy rating with a C$5.00 target as of June 16, 2026, the day after the annual results. Both targets are in Canadian dollars against the TSX line.

The aggregated consensus figures diverge by more than they usually do, which is itself informative. Different data vendors currently show seven analysts with a hold consensus and an average target near US$1.78, seven analysts with an underweight consensus and an average near US$1.64 within a US$0.50 to US$3.20 range, and a third count showing two buys and six holds with an average close to US$1.23. When three vendors covering the same stock disagree by a factor of nearly three on the average target, the honest conclusion is that there is no consensus to quote.

The more useful question is not where the targets sit but what would have to be true for any of them to be reached. On the upside, that means a printed quarter showing the adjusted-EBITDA trajectory the company has guided to, gross margin recovering from the 12% reported in Q4 FY2026, MTL contributing without further inventory charges, Storz & Bickel stabilising, and no additional equity issued into the recovery. On the downside, it means the reverse of each, plus continued use of the remaining ATM capacity.

Retail sentiment is thin and heavily contaminated. A scan of social posts on $CGC over July 28 and 29, 2026 found roughly half of the sample to be promotional spam pushing messaging groups rather than commentary on the company. The genuine posts cluster on two topics: the expected timing of the administrative law judge’s recommendation, and technical levels on the $MSOS ETF. Reddit activity on the ticker is largely dormant, with the most substantive threads dating from autumn 2025. These are the opinions of non-professional traders rather than analysis, and the notable point is the absence of retail engagement, which is itself a change from the sector’s past behaviour.

21 Timeline of Key Developments

December 15, 2023 — One-for-ten reverse split

Canopy completed a one-for-ten share consolidation to address a Nasdaq minimum bid issue, trading post-consolidation from December 20. Relevant precedent for the resolution now on the ballot.

April 2024 — Exchangeable share structure approved

Shareholders approved the creation of exchangeable shares to support the Canopy USA structure and the U.S. THC strategy.

August 29, 2025 — US$200M at-the-market programme

A second ATM programme was established, running to June 5, 2027. It became the main funding source for the balance-sheet repair.

December 18, 2025 — U.S. executive order on cannabis research

Executive Order 14370, “Increasing Medical Marijuana and Cannabidiol Research,” pushed rescheduling back onto the federal agenda and triggered the largest cannabis-sector rally of the cycle. It coincides with the high of the current price range.

January 8, 2026 — Recapitalisation completed

US$150 million drawn on a US$162.1 million senior secured term loan, plus C$55.0 million of 7.50% convertible debentures due 2031. All debt maturities extended to at least January 2031.

March 16, 2026 — MTL Cannabis acquisition completed

Canopy acquired 100% of MTL for approximately 41.2 million shares plus C$18.5 million in cash, MTL contributed 13.4% of total assets but only 1.2% of FY2026 revenue.

April 23 and 28, 2026 — Narrow medical Schedule III order

The Justice Department announced, and the Federal Register published, a final order moving FDA-approved and state-licensed medical marijuana products to Schedule III under the treaty route. Bulk and adult-use cannabis stayed in Schedule I.

May 15, 2026 — Restatement and cease trade order

Canopy disclosed non-cash warrant classification errors affecting FY2024, FY2025 and interim periods, and voluntarily sought a management cease trade order pending the refiling.

May 29, 2026 — Tweed relaunched in Germany

First international product release after the MTL acquisition, using MTL-derived genetics.

June 15, 2026 — FY2026 results and comprehensive 10-K

Revenue of C$284.6 million, a C$20.2 million adjusted EBITDA loss, C$364.7 million of cash, and internal control over financial reporting reported as not effective. The same day, lenders imposed the Canopy USA exchange restriction.

June 29 – July 15, 2026 — DEA administrative hearing

Seventeen hearing days before Chief ALJ Derek C. Julius, closing with final arguments on July 15. Post-hearing briefs due August 17; no deadline on what follows.

July 17, 2026 — Preliminary proxy filed

Canopy asks shareholders to authorise a one-for-five to one-for-fifteen share consolidation at the September 25 meeting, citing the Nasdaq minimum bid price rule.

July 24, 2026 — Q1 FY2027 date confirmed

Results for the quarter ended June 30, 2026 scheduled for August 7 before market open, with a webcast at 10:00 a.m. ET.

August 7, 2026 — Q1 FY2027, definitive proxy and a new auditor

Revenue of C$81.2 million and a C$3.2 million adjusted EBITDA loss, the definitive proxy for the September 25 meeting, and the resignation of PKF O'Connor Davies with MNP LLP engaged the same day for fiscal 2027.

August 17, 2026 — Meeting materials mailed, DEA briefs filed

Canopy mailed the proxy materials and urged early voting ahead of the quorum threshold. On the same day the post-hearing briefs in the DEA proceeding were filed, with the Government asking for Schedule III and every designated party asking that marijuana stay in Schedule I.

22 Bull Case

The bull case for Canopy is that the company has finally moved from survival repair to measurable execution. The balance sheet is stronger, free cash outflow is much lower, Canadian medical cannabis is growing, MTL adds strategic depth, Europe can improve from a low base, and management has set a clear FY2027 adjusted EBITDA goal. In a sector where many companies still struggle with leverage, tax pressure, liquidity and investor fatigue, a recognizable Nasdaq-listed cannabis name with net cash and operating momentum can attract attention quickly.

A favorable U.S. policy backdrop would add fuel. If the DEA hearing process keeps Schedule III momentum alive, liquid cannabis tickers can become retail and thematic vehicles again. CGC may not be a direct U.S. operator, but it is one of the most accessible Nasdaq symbols for traders who want cannabis exposure without using OTC MSOs. That liquidity premium can matter during sector rallies.

The first testable version of that case arrived on August 7, 2026, and it came back mixed: margin and adjusted EBITDA moved toward the target, free cash flow moved away from it. The strongest version of the bull case is not simply “cannabis goes up.” It is this: Canopy reaches positive adjusted EBITDA during FY2027, MTL integration improves gross margin and supply, Canadian medical cannabis remains a credible growth pillar, Storz & Bickel stabilizes, Europe begins to contribute more consistently, and Canopy USA optionality becomes more valuable under a better U.S. regulatory framework.

23 Bear Case

The bear case starts with the simple fact that Canopy is still lossmaking. FY2026 net loss from continuing operations was C$262.9 million. Adjusted EBITDA was still negative. Free cash flow was still negative. Gross margin declined on an as-reported basis. Storz & Bickel declined. The company had to restate prior-period financials because of warrant accounting classification. Shares outstanding expanded sharply. Those are not small issues.

The second part of the bear case is that cannabis investors have been disappointed many times before. The sector has repeatedly produced strong narratives, then missed on execution, pricing, margins, legalization timing, profitability and capital discipline. Canopy carries that history more than almost any other ticker because it was one of the symbols of the original cannabis boom.

The third part is that U.S. optionality may remain optional for longer than bullish traders expect. Schedule III is not legalization, legal challenges are possible, recreational cannabis remains politically and legally complex, and Canopy USA is not a simple consolidated revenue engine today. If the market prices CGC as if U.S. reform is immediate and comprehensive, the stock can be vulnerable to disappointment.

Finally, the sub-dollar zone has stopped being theoretical. The stock closed below US$1.00 for seventeen consecutive sessions through July 28, 2026, and on July 17 the company asked shareholders for authority to consolidate its shares at a ratio of up to one-for-fifteen, citing the Nasdaq minimum bid price rule by name. No deficiency notice has been disclosed, and none should be assumed. But the market remembers the 2023 minimum-bid problem and the one-for-ten split that followed, and it will remember that the share count has since grown from 183.9 million to 422.2 million.

24 Scenario Map

Constructive scenario

DEA proceedings keep cannabis sentiment alive, Canopy reports FY2027 quarters showing lower adjusted EBITDA losses or positive adjusted EBITDA, MTL integration supports margin, Canadian medical cannabis continues growing, Storz & Bickel stabilizes, and dilution fears ease. In this scenario, the stock can regain a stronger thematic premium.

Neutral scenario

Canopy improves slowly but not dramatically. Cannabis revenue grows, but margins remain uneven. Schedule III headlines support trading interest but not a durable re-rating. The stock remains volatile and highly sensitive to sector flows, with valuation anchored by execution uncertainty.

Negative scenario

FY2027 EBITDA progress disappoints, Storz & Bickel remains weak, MTL integration costs pressure margins, Europe fails to scale, cash burn remains material, and the market starts pricing additional dilution. A narrow or delayed U.S. policy outcome would worsen the pressure.

Trading scenario

$CGC moves primarily as a cannabis-policy beta vehicle. In this case, price action may be driven more by DEA headlines, retail flows, options activity and sector momentum than by quarterly fundamentals. This is tradable, but it is not the same as a confirmed operating turnaround.

25 Red Flags to Monitor

26 How to Read $CGC From Here

The cleanest way to read Canopy Growth from here is to separate the stock into two layers. The first layer is the trading layer: cannabis-policy headlines, DEA hearing developments, Schedule III speculation, sector ETF flows, retail attention and sub-$1 psychology. That layer can move the stock quickly and violently.

The second layer is the operating layer: Canadian medical cannabis, MTL integration, adult-use execution, international medical growth, Storz & Bickel stabilization, cash burn and adjusted EBITDA. That layer moves more slowly, but it determines whether rallies can survive after the headline fades.

Short-horizon activity concentrates on the first layer; the second is what determines whether any of it lasts. The problem with cannabis equities over the past several years is that the first layer repeatedly promised what the second could not yet deliver. What has changed for CGC is that the second layer is now more measurable than it was during the broken part of the cycle. What has not changed is that it remains unproven.

The bottom line: $CGC is not a clean “cannabis legalization” story. It is a recapitalized turnaround with medical cannabis momentum, MTL integration upside, U.S. THC optionality and a major FY2027 profitability test, carried by a company that is still lossmaking and still able to issue equity.

27 Merlintrader Bottom Line

For most of the first half of 2026 Canopy was a company waiting: for a regulatory hearing, and for an operating year to be reported. The waiting now has a structure, and one of its terms has been settled. The hearing record closed on July 15 with no decision and no deadline. The first quarter of FY2027 was reported on August 7. A share consolidation authorisation goes to a vote on September 25. And the share price spent all of July below the level at which Nasdaq’s bid-price rule starts a clock.

What has not changed is the underlying arithmetic. Canopy has C$336.6 million of cash after the first quarter, down C$28.1 million in three months, and a net cash position for the first time in years, and it bought that position by increasing the share count from 183.9 million to 422.2 million in twelve months. It has a revenue base growing at 6%, a cannabis segment growing at 15%, a device business shrinking at 14%, an adjusted EBITDA loss of C$20.2 million and free cash outflow of C$69.1 million. It has a target of positive adjusted EBITDA during FY2027 that has not yet met a single reported quarter.

The U.S. option is real and, for now, contractually shut. Canopy USA holds Acreage, Wana, Jetty and a large TerrAscend position, and since June 15 the lenders have blocked the mechanism through which Canopy could convert its interest. A broader Schedule III outcome would raise the value of what sits behind that door without opening it. Meanwhile the operators best placed to capture 280E relief are the U.S. multi-state companies, which is exactly the group that has held up better in the 2026 tape.

That leaves a clear division of labour for anyone following the name. The trading layer is the policy calendar, the dollar level and sector flow, and it moves fast. The operating layer is gross margin after MTL, whether the ATM is used, and whether the control environment is repaired, and it moves slowly. The mistake this sector rewards least is confusing the two: over the past three years, the first layer has repeatedly promised what the second could not deliver.

The August 7 quarter was the first piece of that operating layer that cannot be argued with, and it answered in two directions at once. The trajectory management described is visible in the margin and in the adjusted EBITDA loss, which fell to C$3.2 million from C$7.9 million and puts the FY2027 positive target within a few million dollars a quarter. It is not visible in the cash, where the outflow more than doubled to C$25.7 million and the balance fell C$28.1 million in three months. A company whose reported loss is shrinking while its cash is leaving faster has bought itself margin progress, not time. The next reported quarter, not the September 25 vote, is where that tension gets resolved.

The block below is a snapshot of the Stocktwits flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.

28 Related Merlintrader Reading

• Cannabis Stocks HUB 2026: A Possible Reset for a Broken Sector $MSOS, $TLRY, $CGC, $CRON, $ACB
• DEA Cannabis Hearing Begins: Why Schedule III Still Matters for $TLRY, $CGC and $MSOS
• Tilray Brands (Nasdaq: $TLRY): Cannabis, Beverage and Medical Cannabis Stock Hub
• Cannabis Stocks Watchlist April 2026